VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 71 filers reported holding VERONA PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $678,000 | -16.1% | 161,897 | 0.0% | 0.19% | +7.8% |
Q1 2022 | $808,000 | -25.7% | 161,897 | 0.0% | 0.18% | -8.7% |
Q4 2021 | $1,088,000 | +22.7% | 161,897 | 0.0% | 0.20% | +122.7% |
Q3 2021 | $887,000 | -16.2% | 161,897 | 0.0% | 0.09% | -29.6% |
Q2 2021 | $1,059,000 | -21.7% | 161,897 | 0.0% | 0.12% | -3.1% |
Q1 2021 | $1,353,000 | -2.9% | 161,897 | -18.7% | 0.13% | +4.9% |
Q4 2020 | $1,394,000 | +12.2% | 199,075 | 0.0% | 0.12% | -34.9% |
Q3 2020 | $1,242,000 | -41.9% | 199,075 | -56.4% | 0.19% | -89.4% |
Q2 2020 | $2,138,000 | +13.6% | 456,770 | 0.0% | 1.78% | +10.8% |
Q1 2020 | $1,882,000 | -62.6% | 456,770 | -47.8% | 1.60% | -25.6% |
Q4 2019 | $5,031,000 | +25.8% | 875,000 | 0.0% | 2.16% | +13.7% |
Q3 2019 | $3,999,000 | -10.4% | 875,000 | 0.0% | 1.90% | -4.2% |
Q2 2019 | $4,463,000 | -21.5% | 875,000 | 0.0% | 1.98% | -57.0% |
Q1 2019 | $5,688,000 | -32.6% | 875,000 | 0.0% | 4.61% | -79.2% |
Q4 2018 | $8,444,000 | – | 875,000 | – | 22.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |